Clinical trial
Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events
NCT00190593 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 1998
- Completion date
- November 30, 2005
- Enrollment
- 10,000
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.